Deal-Making

Affibody contracts 3P for psoriasis protein scale-up

Contract development and manufacturing organization (CDMO) 3P Biopharmaceuticals will scale-up the manufacture of Affibody’s candidate ABY-035 for psoriasis. Swedish biopharma firm Affibody has been working with 3P since 2017 and has now secured the CDMO to transfer and scale-up the process developed prior to execution of the first GMP manufacturing batches for its candidate ABY-035. 3P will also carry out process characterization and validation ahead of commercial manufacture. “Currently the collaboration is based on GMP manufacturing for Ph II clinical…

Zolgensma approval marks success for REGENXBIO’s vector platform

REGENXBIO could receive up to $80 million after the US FDA approved Novartis/AveXis’ gene therapy Zolgensma (onasemnogene abeparvovec), which uses the firm’s NAV Technology Platform. Last week, the US Food and Drug Administration (FDA) approved Zolgensma, a single-dose gene therapy developed by Novartis acquisition AveXis, for the treatment of children less than two years of age with spinal muscular atrophy (SMA). The approval triggered a $3.5 million (€3.1 million) milestone payment to Maryland-based biotech REGENXBIO. Zolgensma is based on REGENXBIO’s…

Novartis to end $300m a year facility services deal with ISS

Eight years after inking a deal to provide facilities services across 22 sites, Danish firm ISS says Novartis is unlikely to extend its contract beyond December. In August 2012, Swiss pharma firm Novartis inked a deal with Danish facilities services provider ISS to provide integrated facilities services at 22 sites, including numerous production plants. The deal included the fulfilment of services including catering, property, cleaning, support and security at five sites in Switzerland, eleven sites in Germany, two in Austria,…

ProBioGen licenses duck cell line tech to Vaccitech for viral vaccines

Vaccitech has licensed the AGE1.CR duck retina cell line from ProBioGen to manufacture its viral vectored vaccines. The deal will see University of Oxford’s Jenner Institute spin-out Vaccitech gain access to ProBioGen’s technology platform based on the AGE1.CR duck retina cell line for production of its viral vectored universal flu vaccine. “We generated the AGE1.CR cell line from an embryonated Muscovy duck egg,” Ingo Jordan, director of Vaccine Strategies at ProBioGen told Bioprocess Insider. This, he explained, makes it well…

WuXi scouts single-use site for Chinese vaccine joint venture

WuXi Biologics has formed a vaccine production division to service a $3 billion strategic partnership with an unnamed global pharma. WuXi Vaccines is a joint venture between contract development and manufacturing (CDMO) WuXi Biologics and Shanghai-based Hile Bio-Technology. The new entity has been formed to service a Letter of Intent (LOI) inked with a multinational vaccine company. The client has not been disclosed, but WuXi Biologics CEO Chris Chen told Bioprocess Insider the strategic partnership will allow the vaccine developer…

Evotec lays down $90m to buy Just for kickstarting biologics biz

German services firm Evotec has jumped into the biologics development space through the acquisition of Just.Bio, a platform company working to reduce the cost of goods for proteins. Hamburg, Germany-based Evotec uses its expertise and technologies to help pharma firms discover and develop new small molecule therapies and names Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, and UCB among its partners. Through the addition of Just.Bio for $90 million (€81 million) cash, Evotec has increased its…

Cryoport acquires Cryogene for $20.5m, adds Texas biostorage site

The combination of cold-chain logistics and biostorage places Cryoport in good stead for the arrival of allogeneic cell therapies, an analyst says. Cryogene’s proximity to Lonza’s Houston site is also a boon. Cryoport, a provider of temperature-controlled logistics solutions specifically in the cell and gene therapy space, paid $20.5 million (€18.3 million) in cash for Houston, Texas-based biostorage and biobanking firm Cryogene. Cryogene brings a 21,000 square-foot biostorage facility – which specializes storing biological specimens, materials and samples – to…

CDMO round-up: News from Patheon, Samsung and Sekisui

Patheon will produce an antibody for Cantargia; GI Innovation has signed a second development services deal with Samsung BioLogics; Sekisui Diagnostics is growing its contract microbial manufacturing business. Welcome to Bioprocess Insider’s CDMO round-up. First up in our contract development and manufacturing organization (CDMO) round-up is news from Thermo Fisher’s Patheon, which has been selected to produce CAN04 (nidanilimab) for Cantargia AB. Cantargia already has a contract in place with Celonic (formerly Glycotope Biotechnology) for clinical supply of the monoclonal…

Fungal infection? Biopharma embrace boosts Dyadic’s high titer platform

Dyadic Internationally has struck three deals in two weeks as its industrially-proven fungus-based expression system receives the attention of biotech and Big Pharma. Dyadic reported a busy first quarter 2019 with R&D revenues of $403,000 (€359,000), more than double the same period 2018. The firm also updated investors on recent activity, specifically a wave of deals over the past few weeks supporting its C1 gene expression platform. In April, Australia’s Luina Bio struck a sub-licensing deal with Dyadic, and a…

Subcutaneous success a boon for Halozyme, but biosimilars hit royalties

Roche’s subcutaneous Herceptin (trastuzumab) recently became the third product to be approved using Halozyme Therapeutics’s ENHANZE drug delivery tech. However, Halozyme’s royalties have been hit by biosimilar competition. Halozyme Therapeutics reported what it described as a “strong start to 2019” with revenues of $57 million (€51 million) – up 84% year-on-year – attributed to $30 million upfront license fee from a license agreement struck with argenx in February. That deal gives argenx access to Halozyme’s ENHANZE drug delivery technology to…